This clinical study will move the BT Test forward in its FDA approval as first a supplementary and then a stand-alone screening tool for early breast cancer detection. With fewer false negative and false positive diagnoses, this cost-effective blood test may not only offer vastly superior early-detection capabilities in routine examinations, but may also help patients avoid unnecessary needle biopsies.
| |